0.8242
price down icon0.70%   -0.0058
after-market 시간 외 거래: .83 0.0058 +0.70%
loading
전일 마감가:
$0.83
열려 있는:
$0.83
하루 거래량:
589.55K
Relative Volume:
0.88
시가총액:
$114.38M
수익:
-
순이익/손실:
$-26.91M
주가수익비율:
-3.7464
EPS:
-0.22
순현금흐름:
$-19.57M
1주 성능:
-0.22%
1개월 성능:
+6.06%
6개월 성능:
-12.70%
1년 성능:
-31.32%
1일 변동 폭
Value
$0.8201
$0.8465
1주일 범위
Value
$0.805
$0.92
52주 변동 폭
Value
$0.5526
$1.66

Atossa Therapeutics Inc Stock (ATOS) Company Profile

Name
명칭
Atossa Therapeutics Inc
Name
전화
206.588.0256
Name
주소
10202 5TH AVENUE NE, SEATTLE, WA
Name
직원
13
Name
트위터
@atossainc
Name
다음 수익 날짜
2025-03-25
Name
최신 SEC 제출 서류
Name
ATOS's Discussions on Twitter

ATOS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ATOS
Atossa Therapeutics Inc
0.8242 114.38M 0 -26.91M -19.57M -0.22
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2018-01-26 개시 Maxim Group Buy

Atossa Therapeutics Inc 주식(ATOS)의 최신 뉴스

pulisher
Jun 15, 2025

Millennium Management LLC Purchases Shares of 29,149 Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

Jun 15, 2025
pulisher
Jun 09, 2025

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Purchased by Two Sigma Advisers LP - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Ascendiant Capital Markets Issues Positive Forecast for Atossa Therapeutics (NASDAQ:ATOS) Stock Price - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

Craig Hallum Upgrades Atossa Therapeutics (NASDAQ:ATOS) to “Strong-Buy” - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Atossa Therapeutics (ATOS): Ascendiant Capital Raises Price Targ - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Ascendiant Capital raises Atossa Genetics stock price target to $7.50 By Investing.com - Investing.com India

Jun 06, 2025
pulisher
Jun 06, 2025

Ascendiant Capital raises Atossa Genetics stock price target to $7.50 - Investing.com

Jun 06, 2025
pulisher
Jun 06, 2025

Craig-Hallum Initiates Coverage of Atossa Therapeutics (BMV:ATOS) with Buy Recommendation - Nasdaq

Jun 06, 2025
pulisher
Jun 05, 2025

Craig-Hallum Initiates Coverage of Atossa Therapeutics (ATOS) with Buy Recommendation - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Jun 05, 2025
pulisher
Jun 05, 2025

Craig-Hallum Initiates Coverage on Atossa Therapeutics (ATOS) with Buy Rating | ATOS Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Atossa Therapeutics at Jefferies Conference: Strategic Moves in Breast Cancer - Investing.com Canada

Jun 05, 2025
pulisher
Jun 05, 2025

Craig-Hallum initiates Atossa Genetics stock with buy rating By Investing.com - Investing.com UK

Jun 05, 2025
pulisher
Jun 05, 2025

Atossa Therapeutics (ATOS) Receives Buy Rating with Promising Ca - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Atossa Therapeutics (ATOS) Receives Buy Rating with Promising Cancer Drug Potential | ATOS Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Craig Hallum Initiates Coverage on Atossa Therapeutics With Buy Rating, $4 Price Target - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Atossa Therapeutics (ATOS) Receives Positive Coverage and Price Target | ATOS Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 02, 2025

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference - Bluefield Daily Telegraph

Jun 02, 2025
pulisher
Jun 02, 2025

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference | ATOS Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Atossa Therapeutics CEO Reveals Latest Breast Cancer Drug Progress at Major Healthcare Conference - Stock Titan

Jun 02, 2025
pulisher
May 30, 2025

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Northern Trust Corp - Defense World

May 30, 2025
pulisher
May 28, 2025

Atossa Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 28, 2025
pulisher
May 22, 2025

Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock - Investing.com Australia

May 22, 2025
pulisher
May 22, 2025

Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock By Investing.com - Investing.com Nigeria

May 22, 2025
pulisher
May 22, 2025

Transcript : Atossa Therapeutics, Inc.Special Call - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 - ACCESS Newswire

May 22, 2025
pulisher
May 20, 2025

Atossa Therapeutics announces issuance of U.S. patent - MSN

May 20, 2025
pulisher
May 20, 2025

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 | ATOS Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Atossa CEO to Reveal Latest Phase 2 Results for Next-Gen Breast Cancer Drug in Exclusive Investor Webinar - Stock Titan

May 20, 2025
pulisher
May 18, 2025

HC Wainwright Issues Optimistic Outlook for ATOS Earnings - Defense World

May 18, 2025
pulisher
May 15, 2025

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? - Yahoo Finance

May 15, 2025
pulisher
May 14, 2025

Atossa Therapeutics (ATOS) Reports Promising Phase 2 Trial Resul - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Atossa Therapeutics Announces Full Results from I?SPY?2 Endocrin - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen - StreetInsider

May 14, 2025
pulisher
May 14, 2025

Wells Fargo & Company MN Has $68,000 Stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

May 14, 2025
pulisher
May 14, 2025

Phase 2 Trial: New Breast Cancer Drug Achieves 77.7% Tumor Shrinkage with Minimal Side Effects - Stock Titan

May 14, 2025
pulisher
May 13, 2025

Atossa Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Atossa Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025
pulisher
May 13, 2025

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update - goSkagit

May 13, 2025
pulisher
May 13, 2025

ATOSSA THERAPEUTICS, INC. SEC 10-Q Report - TradingView

May 13, 2025
pulisher
May 13, 2025

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update | ATOS Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Barclays PLC Has $181,000 Holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

May 13, 2025
pulisher
May 10, 2025

Atossa Therapeutics (ATOS) to Release Quarterly Earnings on Monday - Defense World

May 10, 2025
pulisher
May 08, 2025

Atossa Therapeutics reports progress in breast cancer treatments - MSN

May 08, 2025
pulisher
May 05, 2025

Atossa Therapeutics and Ainos Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - standard-journal.com

May 05, 2025
pulisher
May 03, 2025

JPMorgan Chase & Co. Buys 211,654 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

May 03, 2025
pulisher
May 02, 2025

ATOS: Atossa Therapeutics Secures New Patent for (Z)-endoxifen F - GuruFocus

May 02, 2025
pulisher
May 02, 2025

ATOS: Atossa Therapeutics Secures New Patent for (Z)-endoxifen Formulations | ATOS Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

A look into Atossa Therapeutics Inc (ATOS)’s deeper side - Sete News

May 02, 2025
pulisher
May 02, 2025

LPL Financial LLC Cuts Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

May 02, 2025

Atossa Therapeutics Inc (ATOS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Atossa Therapeutics Inc 주식 (ATOS) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Remmel H. Lawrence
Director
Mar 26 '25
Buy
0.70
10,000
7,000
10,257
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
자본화:     |  볼륨(24시간):